- Home
- TIL vs RDCM Comparison
TIL vs RDCM Comparison
Compare TIL & RDCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIL
- RDCM
- Stock Information
- Founded
- TIL 2018
- RDCM 1985
- Country
- TIL United States
- RDCM Israel
- Employees
- TIL N/A
- RDCM N/A
- Industry
- TIL Biotechnology: Pharmaceutical Preparations
- RDCM Computer peripheral equipment
- Sector
- TIL Health Care
- RDCM Technology
- Exchange
- TIL Nasdaq
- RDCM Nasdaq
- Market Cap
- TIL 177.1M
- RDCM 203.7M
- IPO Year
- TIL 2021
- RDCM 1997
- Fundamental
- Price
- TIL $17.27
- RDCM $13.61
- Analyst Decision
- TIL Strong Buy
- RDCM Strong Buy
- Analyst Count
- TIL 5
- RDCM 1
- Target Price
- TIL $100.67
- RDCM $18.00
- AVG Volume (30 Days)
- TIL 97.5K
- RDCM 44.2K
- Earning Date
- TIL 11-13-2025
- RDCM 11-12-2025
- Dividend Yield
- TIL N/A
- RDCM N/A
- EPS Growth
- TIL N/A
- RDCM 79.61
- EPS
- TIL N/A
- RDCM 0.56
- Revenue
- TIL N/A
- RDCM $66,334,000.00
- Revenue This Year
- TIL N/A
- RDCM $18.07
- Revenue Next Year
- TIL N/A
- RDCM $11.52
- P/E Ratio
- TIL N/A
- RDCM $24.36
- Revenue Growth
- TIL N/A
- RDCM 18.18
- 52 Week Low
- TIL $10.80
- RDCM $9.81
- 52 Week High
- TIL $44.50
- RDCM $15.98
- Technical
- Relative Strength Index (RSI)
- TIL 40.68
- RDCM 45.99
- Support Level
- TIL $17.44
- RDCM $13.57
- Resistance Level
- TIL $20.11
- RDCM $14.71
- Average True Range (ATR)
- TIL 1.29
- RDCM 0.53
- MACD
- TIL -0.00
- RDCM -0.02
- Stochastic Oscillator
- TIL 1.61
- RDCM 30.60
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.